Immuneering Corporation, a clinical-stage oncology company, has announced a definitive securities purchase agreement for a private placement expected to generate approximately $25 million in gross proceeds. This transaction involves the sale of 6,329,113 unregistered shares of Class A common stock at $3.95 per share, alongside purchase warrants for an additional 2,848,096 shares at an exercise price of $5.50 per share. The purchase price represents a 15% premium over the company's last reported closing price. The funds will support the continued development of Immuneering's innovative cancer treatments, particularly their Deep Cyclic Inhibitor, atebimetinib. The closing of the private placement is contingent upon customary conditions and is anticipated to occur on or about August 26, 2025.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。